Biotechnology Value Fund

Biotechnology Value Fund


Relay Therapeutics Snaps up ZebiAI with $85 Million Upfront Payment

$85,000,000 Venture capital (Series C)

Olema Oncology Raises $85M in Series C Financing

MedCity News

FDA green-lights second RET inhibitor, this time from Blueprint Medicines


Kymera Therapeutics Unveils IPO Pitch for Protein Degradation

$54,000,000 Venture capital (Series B)
Pulse 2.0 , FinSMEs

Olema Oncology Secures $54 Million To Advance Lead Program In Breast Cancer

MedCity News

Relay Therapeutics prices IPO at $400M

Bloomberg Technology

SoftBank-Backed Relay Therapeutics Seeks $265 Million in IPO

MedCity News

Protein motion-focused Relay Therapeutics files for $200M IPO

$76,000,000 Venture capital (Series B)
Pulse 2.0

Autobahn Therapeutics Raises $76 Million To Develop Therapies For CNS Disorders


Autobahn Therapeutics Raises $76M in Series B Financing

the home of AI info

Evotec, Takeda Enter Long-Term Research Alliance

$102,000,000 Venture capital (Series C)

Kymera Therapeutics Raises $102M in Series C Financing


Evotec CEO Discusses Ways to Make Drug R&D Faster and Better

$181,700,000 IPO

Phathom Pharmaceuticals goes public

$400,000,000 Venture capital (Series C)
FinSMEs , PE HUB , VentureBeat

Relay Therapeutics Secures $400M in Series C Financing

$65,000,000 Venture capital (Series B)

Kymera Therapeutics attracts $65 mln Series B

$18,400,000 Venture capital (Series A)
MedCity News

Rain Therapeutics scores $18 million Series A round for lung cancer drug

$35,000,000 Venture capital (Series B)
PE HUB , Venture Funding News

ViewPoint Therapeutics attracts $35 mln Series B

$75,000,000 Venture capital (Series A)
Xconomy , FinSMEs

Prevail Gets $75M For Parkinson’s Gene Therapy, Bolstering NY Biotech

Health Funding Science
$60,000,000 Post-IPO equity
bizjournals , 512tech